Overview

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Mirati Therapeutics Inc.